GLP-1 Peptide Research Guide: Semaglutide, Tirzepatide & Retatrutide

GLP-1 receptor agonists have become the most extensively studied peptide class in metabolic biology. Semaglutide, tirzepatide, and retatrutide represent three successive generations of incretin-based design. Each adds a receptor target to the previous generation, and each has generated a distinct body of preclinical and clinical trial literature.

This pillar guide covers the mechanism, trial evidence, research applications, and storage requirements for all three compounds. It is intended as the canonical GLP-1 reference for the CertaPeptides research library and links out to deeper single-compound articles for each molecule.

All information in this article is intended for laboratory and research purposes only. It is not medical advice, not a dosing recommendation for humans, and not an endorsement of any non-research use. Clinical trial data is summarised strictly as research context.

What are GLP-1 receptor agonists?

GLP-1 receptor agonists are synthetic peptides that mimic the incretin hormone glucagon-like peptide-1. In research contexts, they interact with the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor.

The receptor is expressed across pancreatic beta cells, the central nervous system, gastric tissue, and several peripheral metabolic sites. Its downstream signalling runs primarily through cAMP and PKA pathways, with secondary input into PI3K/Akt and MAPK cascades.

Incretin peptides are a core tool in metabolic research because they allow selective, pharmacological activation of pathways that are otherwise regulated by post-prandial physiology. The peptide class lets researchers isolate receptor-level effects from the confounders of whole-body glucose dynamics.

Researchers typically work with these compounds across a defined set of assay types. Common categories include receptor binding and selectivity assays, cAMP accumulation and beta-arrestin recruitment functional assays, insulin secretion studies in pancreatic beta cell lines, structure-activity relationship work, and pharmacokinetic profiling in animal models.

The class has also driven substantial interest in half-life extension chemistry. Fatty acid conjugation, used in semaglutide, is now a reference strategy for extending peptide exposure through reversible albumin binding (Knudsen and Lau, 2019; PMID: 30984108).

For researchers, the practical consequence is that incretin peptides now form one of the best-characterised target classes in metabolic biology. There is a dense layer of receptor binding data, signalling pathway analysis, and comparative assay results that can be used as a reference base when designing new SAR or pharmacokinetic experiments.

The three compounds covered below are the flagship research tools in that class. Each has published evidence in cell-based assays, animal models, and clinical trial programs that research teams can cite as context for further preclinical work.

Evolution of incretin design: GLP-1 to dual to triple agonist

The trajectory from single-receptor GLP-1 agonists to triple agonists is one of the clearest examples of iterative peptide engineering in the recent literature. Each generation adds receptor coverage without sacrificing the half-life gains of the previous step.

First-generation GLP-1 agonists such as exenatide and liraglutide validated the target. They showed that sustained GLP-1R activation could modulate glucose handling and appetite circuitry in preclinical and clinical trial settings, but the short half-life of native GLP-1 remained a chemistry problem.

Semaglutide solved the half-life problem by adding a C-18 fatty diacid to position 26, enabling reversible albumin binding. The same scaffold became the launchpad for exploring whether adding a second incretin receptor could improve metabolic coverage further.

Tirzepatide answered that question by integrating GIP agonism. Co-activation of GIP and GLP-1 receptors produced a different signalling profile than either alone (Frias et al., 2021; PMID: 34170647). The GIP contribution, long considered weak in monotherapy, became measurable in combination.

Retatrutide then added glucagon receptor agonism on top of the GIP/GLP-1 framework. The glucagon arm is the most mechanistically distinctive element because it is associated with hepatic glucose output and energy expenditure effects that the two incretin arms alone do not produce (Jastreboff et al., 2023; PMID: 37366315).

The progression from single to dual to triple agonist is not just a story of adding receptors. It is also a story of preserving the engineering gains of the earlier generations. Each new compound inherits the half-life extension strategies established by the previous generation, then layers additional receptor coverage on top.

This matters for research design. The differences between the three compounds in a given assay are usually driven by receptor profile rather than by pharmacokinetic confounders, which makes them a relatively clean comparison set for mechanism-focused work.

It is worth noting that broader receptor coverage is not automatically better in every context. Each additional receptor arm also adds a set of off-target considerations that preclinical studies must characterise, and the relative contribution of each arm remains an open research question across the class.

Receptor activity at a glance

Compound	GLP-1R	GIP-R	Glucagon-R	Regulatory status	Key trial program
Semaglutide	Full agonist	None	None	FDA approved (T2D, obesity)	STEP, SUSTAIN, SELECT
Tirzepatide	Full agonist	Full agonist	None	FDA approved (T2D, obesity)	SURPASS, SURMOUNT
Retatrutide	Full agonist	Full agonist	Full agonist	Investigational (Phase 3)	TRIUMPH

For a side-by-side comparison covering pharmacokinetics, published potency ratios, and assay-level differentiators, see our head-to-head comparison.

Clinical trial weight-loss outcomes (research context)

The table below summarises published clinical trial outcomes for each compound. It is included strictly as research reference data. It is not a clinical recommendation, not a comparative efficacy claim, and not a basis for any human dosing decision.

Compound	Trial	n	Dose (trial protocol)	Mean % weight change	Duration	Citation
Semaglutide	STEP 1	1961	2.4 mg weekly	-14.9%	68 weeks	PMID: 33567185
Tirzepatide	SURMOUNT-1	2539	15 mg weekly	-20.9%	72 weeks	PMID: 35658024
Retatrutide	TRIUMPH Phase 2	338	12 mg weekly	-24.2%	48 weeks	PMID: 37366315

These trials form the most-cited evidence base in the current literature. They are frequently used as anchor references in preclinical and translational work modelling comparative receptor effects.

Semaglutide research profile

Mechanism	Selective GLP-1 receptor agonist
Molecular weight	~4,113.58 Da
CAS number	910463-68-2
Molecular formula	C187H291N45O59
Sequence length	31 amino acids (modified GLP-1 analog)
Half-life strategy	C-18 fatty diacid at position 26 for albumin binding

Mechanism

Semaglutide is the most extensively studied compound in the class, which makes it the practical baseline for comparative research. Its fatty diacid modification enables reversible albumin binding, which extends functional exposure in animal models and clinical pharmacokinetic studies.

The backbone is a GLP-1 analog with two amino acid substitutions (Aib8 and Arg34) that reduce DPP-4 cleavage and improve stability. The resulting molecule retains high selectivity for GLP-1R without meaningful GIP or glucagon receptor activity.

Key trials (research context)

STEP 1 (Wilding et al., 2021) is the most-cited obesity trial in the literature base (PMID: 33567185). SUSTAIN generated the type 2 diabetes evidence base, and SELECT extended the dataset into cardiovascular outcomes. Each trial program is routinely cited in preclinical papers as the translational reference point.

Research applications

Published research uses semaglutide across several assay categories. These include GLP-1R binding affinity and competitive displacement studies, in vitro insulin secretion studies in pancreatic beta cell lines such as INS-1 and MIN6, cAMP accumulation assays for receptor activation profiling, and appetite regulation pathway studies in animal models.

• In vitro receptor binding assays: concentration ranges reported in the literature of 0.1 nM to 1 microM
• Cell-based functional assays: 1 nM to 100 nM typical working concentrations
• Animal model studies: weight-adjusted protocol concentrations reported in the range of 1 to 60 nmol/kg

For a deeper treatment of semaglutide mechanism, animal model data, and assay selection, see the dedicated semaglutide research article.

Storage

• Lyophilized powder: store at -20 C, stable for 24+ months desiccated
• Reconstituted solution: store at 2 to 8 C, use within 30 days
• Reconstitute with bacteriostatic water or sterile PBS for research applications
• Avoid repeated freeze-thaw cycles

Tirzepatide research profile

Mechanism	Dual GIP / GLP-1 receptor agonist
Molecular weight	~4,813.45 Da
CAS number	2023788-19-2
Molecular formula	C225H348N48O68
Sequence length	39 amino acids
Half-life strategy	C-20 fatty diacid for albumin binding

Mechanism

Tirzepatide is a dual agonist engineered from a modified GIP backbone that also activates GLP-1R. The molecule was designed deliberately around GIP because the GIP component, long considered a weak contributor to glucose control in monotherapy, shows measurable contribution in combination with GLP-1 activation.

The dual receptor profile makes tirzepatide a useful research tool for studying incretin synergy. It lets investigators isolate how co-activating two receptors within the same pathway differs from activating either one alone.

Key trials (research context)

SURPASS-2 (Frias et al., 2021; PMID: 34170647) benchmarked tirzepatide against semaglutide in type 2 diabetes. SURMOUNT-1 then extended the evidence into the obesity population, reporting a mean weight change of -20.9 percent at the 15 mg dose over 72 weeks (PMID: 35658024).

Research applications

Research applications in the published literature include dual receptor selectivity and cross-reactivity profiling, comparative studies of GIP versus GLP-1 receptor signalling pathways, characterisation of synergistic effects on glucose metabolism in cell culture, and lipid metabolism and adipose tissue studies in animal models.

• Receptor binding assays: 0.01 nM to 10 microM for dose-response curves
• Cell-based GIP/GLP-1 activation assays: 0.1 nM to 100 nM working concentrations
• Animal model studies: 1 to 100 nmol/kg weight-adjusted ranges reported in the literature

For more detail on dual-agonist assay design and published SAR work, see the tirzepatide research article.

Storage

• Lyophilized powder: store at -20 C, stable for 24+ months desiccated
• Reconstituted solution: store at 2 to 8 C, use within 28 days
• Protect from light
• Avoid repeated freeze-thaw cycles

Retatrutide research profile

Mechanism	Triple agonist: GIP / GLP-1 / glucagon receptor
Molecular weight	~4,625.25 Da
CAS number	2381089-83-2
Molecular formula	C219H338N48O63
Sequence length	39 amino acids
Half-life strategy	Lipidated backbone supporting extended exposure

Mechanism

Retatrutide adds glucagon receptor agonism to the GIP/GLP-1 dual-agonist framework. The glucagon component is what makes it mechanistically distinct from the earlier generations, because glucagon receptor activation is associated with hepatic glucose output and energy expenditure pathways that the two incretin receptors alone do not engage.

The net metabolic effect of combining all three receptor activities is still an active preclinical and translational research question. Retatrutide is therefore a high-interest research tool precisely because its mechanism is the least settled in the class.

Key trials (research context)

Jastreboff et al. (2023) published the Phase 2 TRIUMPH data in the New England Journal of Medicine, reporting a mean weight change of -24.2 percent at 12 mg over 48 weeks (PMID: 37366315). TRIUMPH-4 subsequently reported Phase 3 data, which our satellite article covers in detail: TRIUMPH-4 results.

Research applications

Research applications in the literature include triple receptor activation profiling and selectivity studies, isolation of the glucagon receptor contribution to metabolic effects, comparative efficacy studies against mono- and dual-agonists, and body composition and lipid metabolism work in animal models.

• In vitro receptor activation assays: 0.01 nM to 1 microM dose-response ranges
• Functional cell-based assays: 1 nM to 100 nM concentrations reported
• Animal model studies: 0.5 to 100 nmol/kg weight-adjusted ranges reported in the literature

For a deeper mechanistic treatment and published SAR comparisons, see the retatrutide research article.

Storage

• Lyophilized powder: store at -20 C, protect from moisture
• Reconstituted solution: store at 2 to 8 C, use within 21 days
• Aliquot reconstituted solutions to minimise freeze-thaw degradation

Analytical comparison across all three compounds

Property	Semaglutide	Tirzepatide	Retatrutide
Receptor targets	GLP-1	GIP + GLP-1	GIP + GLP-1 + glucagon
Molecular weight	~4,113 Da	~4,813 Da	~4,625 Da
Sequence length	31 aa	39 aa	39 aa
CAS number	910463-68-2	2023788-19-2	2381089-83-2
Half-life strategy	C-18 fatty diacid	C-20 fatty diacid	Lipidated backbone
Lyophilized storage	-20 C	-20 C	-20 C
Reconstituted stability	~30 days at 2-8 C	~28 days at 2-8 C	~21 days at 2-8 C
Regulatory status	FDA approved	FDA approved	Investigational (Phase 3)

For pharmacokinetic parameters in more depth, including reported half-life and clearance values, see GLP-1 pharmacokinetics. For working concentration protocols used in published research, see research dosing protocols. For current market context across research suppliers, see current GLP-1 market pricing.

Reconstitution and preparation

For detailed guidance on reconstituting lyophilised peptides, including concentration calculations and syringe volume references, visit our Peptide Reconstitution Calculator.

A few general principles apply to all three compounds. Use bacteriostatic water (0.9 percent benzyl alcohol) when multi-use reconstitution is needed. Add solvent slowly along the vial wall rather than directly onto the powder.

Swirl the vial gently rather than shaking it. Full dissolution typically takes one to three minutes. Label the vial with the reconstitution date and working concentration before returning it to the fridge.

None of these steps constitute a human dosing protocol. They are laboratory handling procedures for research-grade material only.

Working concentrations should be calculated against the peptide content stated on the batch Certificate of Analysis rather than the gross vial mass. This is particularly important for fatty-acid-conjugated compounds such as semaglutide and tirzepatide, where the conjugate mass contributes to total molecular weight but is not pharmacologically active at the receptor.

Frequently asked questions

What is the difference between GLP-1, GIP, and glucagon receptor agonists?

GLP-1 and GIP are both incretin hormones that are released post-prandially and stimulate insulin secretion, but they activate different receptors and have different signalling profiles. Glucagon is a counter-regulatory hormone associated with hepatic glucose output and energy expenditure. A single-receptor GLP-1 agonist like semaglutide activates only the GLP-1 receptor. A dual agonist like tirzepatide activates GLP-1 and GIP. A triple agonist like retatrutide activates all three.

Which GLP-1 research peptide is the most studied?

Semaglutide has the largest published literature base. It has been studied across the STEP, SUSTAIN, and SELECT clinical trial programs, as well as a large volume of preclinical receptor binding, signalling, and animal model work. That depth is why it serves as the comparison baseline in most recent GLP-1 research papers.

What is the strongest receptor profile in the GLP-1 class?

Retatrutide currently has the broadest receptor profile because it activates GLP-1, GIP, and glucagon receptors. Breadth of receptor coverage is not identical to effect magnitude, and the relative contribution of each receptor arm is still an active research question in the preclinical and clinical trial literature.

How should these peptides be stored in a research laboratory?

Lyophilized powder of all three compounds is typically stored at -20 C in a desiccated environment, where stability of 24+ months is commonly reported. Reconstituted solutions are stored at 2 to 8 C, with usable windows of approximately 30 days for semaglutide, 28 days for tirzepatide, and 21 days for retatrutide. Repeated freeze-thaw cycles should be avoided for all three.

Research-grade GLP-1 peptides

CertaPeptides supplies greater than or equal to 99 percent HPLC-verified semaglutide, tirzepatide, and retatrutide with batch-specific Certificates of Analysis. All products are for laboratory and research use only. Browse the full catalog, or contact our research support team with protocol questions.

Free shipping on orders over EUR 150 across the EU.

---

Disclaimer: this article is provided for educational and research reference purposes only. CertaPeptides products are sold exclusively for laboratory and research use. Not for human consumption. Nothing in this article constitutes medical advice, therapeutic recommendation, or dosing guidance for human use. All clinical trial data is reproduced strictly as research context and is attributed to the published source. Always consult peer-reviewed literature for experimental protocol design.

References

1. Drucker DJ. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 27(4), 740-756. PMID: 30078554.
2. Wilding JPH, et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 384(11), 989-1002. PMID: 33567185.
3. Frias JP, et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine, 385(6), 503-515. PMID: 34170647.
4. Jastreboff AM, et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 387(3), 205-216. PMID: 35658024.
5. Jastreboff AM, et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity, a Phase 2 trial. New England Journal of Medicine, 389(6), 514-526. PMID: 37366315.
6. Knudsen LB, Lau J. (2019). The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology, 10, 155. PMID: 30984108.